A flavonoid rich standardized extract of Glycyrrhiza glabra protects intestinal epithelial barrier function and regulates the tight-junction proteins expression.
2,4,6-Trinitrobenzenesulfonic acid
Glycyrrhiza glabra
Intestinal permeability
Leaky gut
TNF-alpha
Tight junction proteins
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
07 Feb 2022
07 Feb 2022
Historique:
received:
14
09
2021
accepted:
24
12
2021
entrez:
8
2
2022
pubmed:
9
2
2022
medline:
12
2
2022
Statut:
epublish
Résumé
Intestinal epithelial barrier dysfunction predisposes to many gastrointestinal, metabolic, and psychological disorders. A flavonoid rich extract of Glycyrrhiza glabra (FREG) has previously been reported to possess anti-inflammatory, antioxidant, and antiulcer properties. To investigate the effect of FREG (GutGard In in vitro, human intestinal Caco-2 cell monolayers were treated with TNF-α in the presence or absence of FREG and the paracellular permeability to FITC-conjugated 4-kD dextran (FD4) was measured to evaluate protection against the barrier dysfunction. In in vivo, intestinal barrier dysfunction was induced in male albino Wistar rats via intrarectal instillation of TNBS. Subsequently, the rats were treated orally with either FREG at 6.25, 12.5, and 25 mg/kg body weight, or Mesacol (250 mg/kg) for 5 days. On day 5, intestinal epithelial permeability was assessed with FD4 leakage into the serum. Also, colonic inflammation, colon morphology, histology and macroscopic score, weight to length ratio were evaluated. The activity of myeloperoxidase (MPO), TNF- α, secretory IgA levels and tight junction proteins expression were evaluated in rat's colon. FREG protected the intestinal epithelial barrier integrity in human intestinal Caco-2 cells in vitro. FREG administration significantly improved the intestinal epithelial barrier function as evident from significant reduction in FD4 leakage. The colon morphology, histology score, macroscopic score, colon weight to length ratio also indicates beneficial effects of FREG on barrier function. In addition, FREG regulated the tight junction proteins, and markedly decreased TNF-α, MPO levels and significantly increased the secretory IgA levels in TNBS induced colitis rats. The study findings support the protective action of FREG on intestinal epithelial barrier integrity indicating its potential in protecting from implications of leaky gut.
Sections du résumé
BACKGROUND
BACKGROUND
Intestinal epithelial barrier dysfunction predisposes to many gastrointestinal, metabolic, and psychological disorders. A flavonoid rich extract of Glycyrrhiza glabra (FREG) has previously been reported to possess anti-inflammatory, antioxidant, and antiulcer properties.
AIM
OBJECTIVE
To investigate the effect of FREG (GutGard
METHODS
METHODS
In in vitro, human intestinal Caco-2 cell monolayers were treated with TNF-α in the presence or absence of FREG and the paracellular permeability to FITC-conjugated 4-kD dextran (FD4) was measured to evaluate protection against the barrier dysfunction. In in vivo, intestinal barrier dysfunction was induced in male albino Wistar rats via intrarectal instillation of TNBS. Subsequently, the rats were treated orally with either FREG at 6.25, 12.5, and 25 mg/kg body weight, or Mesacol (250 mg/kg) for 5 days. On day 5, intestinal epithelial permeability was assessed with FD4 leakage into the serum. Also, colonic inflammation, colon morphology, histology and macroscopic score, weight to length ratio were evaluated. The activity of myeloperoxidase (MPO), TNF- α, secretory IgA levels and tight junction proteins expression were evaluated in rat's colon.
RESULTS
RESULTS
FREG protected the intestinal epithelial barrier integrity in human intestinal Caco-2 cells in vitro. FREG administration significantly improved the intestinal epithelial barrier function as evident from significant reduction in FD4 leakage. The colon morphology, histology score, macroscopic score, colon weight to length ratio also indicates beneficial effects of FREG on barrier function. In addition, FREG regulated the tight junction proteins, and markedly decreased TNF-α, MPO levels and significantly increased the secretory IgA levels in TNBS induced colitis rats.
CONCLUSION
CONCLUSIONS
The study findings support the protective action of FREG on intestinal epithelial barrier integrity indicating its potential in protecting from implications of leaky gut.
Identifiants
pubmed: 35130890
doi: 10.1186/s12906-021-03500-1
pii: 10.1186/s12906-021-03500-1
pmc: PMC8822647
doi:
Substances chimiques
Flavonoids
0
Plant Extracts
0
Tight Junction Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
38Informations de copyright
© 2022. The Author(s).
Références
Nutr Res Rev. 2016 Dec;29(2):234-248
pubmed: 27841104
Front Biosci. 2008 May 01;13:7210-26
pubmed: 18508729
J Allergy Clin Immunol. 2009 Jul;124(1):3-20; quiz 21-2
pubmed: 19560575
Evid Based Complement Alternat Med. 2013;2013:263805
pubmed: 23606875
Eur Rev Med Pharmacol Sci. 2015;19(6):1068-76
pubmed: 25855934
Nat Rev Immunol. 2009 Nov;9(11):799-809
pubmed: 19855405
Sci Rep. 2016 Sep 13;6:32889
pubmed: 27620138
Front Immunol. 2017 May 23;8:598
pubmed: 28588585
J Immunol. 2009 Nov 1;183(9):5879-85
pubmed: 19828639
J Clin Gastroenterol. 2012 Oct;46 Suppl:S52-5
pubmed: 22955358
Pflugers Arch. 2017 Jan;469(1):77-90
pubmed: 27864644
Indian J Exp Biol. 2010 Mar;48(3):269-74
pubmed: 21046980
Cell Mol Gastroenterol Hepatol. 2015 Mar 1;1(2):154-170
pubmed: 26000334
Food Chem Toxicol. 2012 Jul;50(7):2342-8
pubmed: 22542552
Am J Pathol. 2005 Feb;166(2):409-19
pubmed: 15681825
J Agric Food Chem. 2013 Jun 5;61(22):5291-7
pubmed: 23668856
Cell Physiol Biochem. 2012;29(5-6):799-808
pubmed: 22613980
Indian J Pharmacol. 2015 Jan-Feb;47(1):17-21
pubmed: 25821305
BMC Gastroenterol. 2014 Nov 18;14:189
pubmed: 25407511
Cytokine. 2011 Dec;56(3):581-8
pubmed: 21890376
Am J Pathol. 2010 Aug;177(2):512-24
pubmed: 20581053
Neuro Oncol. 2013 Apr;15(4):451-61
pubmed: 23382286
Phytomedicine. 2011 Feb 15;18(4):278-84
pubmed: 20864324
Gut Liver. 2016 May 23;10(3):406-11
pubmed: 27114435
J Biol Chem. 2011 Sep 9;286(36):31263-71
pubmed: 21771795
Phytother Res. 2018 Dec;32(12):2323-2339
pubmed: 30117204
Mediators Inflamm. 2015;2015:628157
pubmed: 26582965
PLoS One. 2014 May 20;9(5):e98016
pubmed: 24845399
Inflamm Bowel Dis. 2011 Jan;17(1):362-81
pubmed: 20725949
Hum Exp Toxicol. 2020 Apr;39(4):477-491
pubmed: 31835924
Clin Exp Immunol. 2008 Jan;151(1):165-73
pubmed: 18005263
Front Biosci (Landmark Ed). 2009 Jan 01;14:2765-78
pubmed: 19273235
Acta Pharmacol Sin. 2017 May;38(5):688-698
pubmed: 28260798
Ann Med Surg (Lond). 2016 Aug 19;11:9-15
pubmed: 27656280
Regul Toxicol Pharmacol. 2011 Dec;61(3):373-80
pubmed: 22019788
Am J Gastroenterol. 1997 Dec;92(12 Suppl):5S-11S
pubmed: 9395346
J Immunol. 2008 Apr 15;180(8):5653-61
pubmed: 18390750
Therap Adv Gastroenterol. 2016 Jan;9(1):37-49
pubmed: 26770266
Exp Mol Med. 2018 Aug 16;50(8):1-9
pubmed: 30115904
Evid Based Complement Alternat Med. 2012;2012:216970
pubmed: 21747893
Nature. 1998 Jan 22;391(6665):393-7
pubmed: 9450756
Gastroenterology. 1989 Mar;96(3):795-803
pubmed: 2914642
Inflamm Bowel Dis. 2011 Nov;17(11):2224-34
pubmed: 21308881
J Nutr. 2013 Jun;143(6):827-34
pubmed: 23596159
J Physiol Pharmacol. 2011 Jun;62(3):347-56
pubmed: 21893696
J Immunol. 2005 Jun 1;174(11):7368-75
pubmed: 15905584
Inflammopharmacology. 2011 Aug;19(4):235-41
pubmed: 21328091
Cell Mol Life Sci. 2013 Feb;70(4):631-59
pubmed: 22782113
Curr Opin Gastroenterol. 2007 Jul;23(4):379-83
pubmed: 17545772
PLoS One. 2013 May 03;8(5):e61944
pubmed: 23671580